Sansheng Pharmaceuticals announced the acceptance of the Beval Pearl single anti-biosimilar drug China IND.

The results of the SB8 Phase III clinical study were published at the 2019 Annual Meeting of the European Society of Oncology (ESMO).
The study was conducted in randomized, double-blind, multi-center form and compared the efficacy, safety, pharmacogenesital dynamics and immunogenicity of SB8 and Avastin in 763 patients with metastasis or relapsed non-squamous non-small cell lung cancer (NSCLC).
data show that SB8 has no clinical difference with Avastin in terms of efficacy, safety, pharmacogenetics and immunogenicity.
-like drug beval-beaded anti-biosynthmics in China will target metastatic colorectal cancer and non-small cell lung cancer.
2015, there were 376,000 new cases of colorectal cancer and 191,000 deaths (incidence 26.6 per 100,000 people, mortality rate of 13.5 per 100,000 people) in China, according to the National Cancer Center. The incidence of colon cancer has increased significantly and is much higher in urban areas than in rural areas, where most patients are found to be in the middle and late stages, while lung cancer is the most morbidity and mortality cancer in China, with 733,000 new cases and 610,000 deaths in 2015.
(incidence 51.9 per 100,000 population, mortality rate 43.2 per 100,000 population).
more than 85% of lung cancer cases are non-small cell lung cancer.
From 2019 onwards, sales revenue in China's Bevalzhu monobial-like drug market is expected to grow at a compound annual growth rate of 343.5%, with a market size of about 6.4 billion yuan in 2023 and 9.9 billion yuan by 2030, according to Frost Sullivan.
.